For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...

The United States pharmaceutical lobby has complained to US President Donald Trump that Australia’s Pharmaceutical Benefits ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The United States pharmaceutical lobby has complained to US President Donald Trump that Australia's Pharmaceutical Benefits ...

and Boehringer Ingelheim/Zealand Pharma start to eye a market that has been estimated to be worth $100 billion within a decade. Data on the subcutaneous version of amycretin is due next year ...

Healthcare & Pharmaceuticalscategory· March 14, 2025 Drugmakers agree to participate in second round of price negotiations All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals ...

Delivering late stage therapeutic pipeline, building the next generation of radiopharmaceuticals, growing industry leading precision medicine business, expanding global infrastructure for product ...

The monument is a frequent magnet for trouble.